MIRA

Efficacy of Ketamir-2: MIRA Pharmaceuticals has demonstrated that its oral ketamine analog, Ketamir-2, significantly reduces neuropathic pain in diabetic rats, outperforming existing FDA-approved medications without causing dissociative effects.

Future Developments: The company plans to initiate a Phase 2a trial for Ketamir-2 by the end of 2025 and is also developing a topical formulation for localized pain relief, while expanding its pipeline through the acquisition of SKNY Pharmaceuticals.

Acquisition Announcement: MIRA Pharmaceuticals signed a letter of intent to acquire SKNY Pharmaceuticals, which includes a $5 million cash infusion to support the development of SKNY-1, a preclinical oral drug candidate for weight loss and smoking cessation.

Strategic Positioning: The acquisition allows MIRA to enter high-growth pharmaceutical markets with SKNY-1, targeting cannabinoid pathways for appetite regulation and nicotine dependence, while also expanding its pain management portfolio with the formulation of Ketamir-2.

MIRA Pharmaceuticals' New Treatment: MIRA Pharmaceuticals Inc. has announced the development of Ketamir-2 as a topical treatment for localized neuropathic and inflammatory pain, expanding its pain management portfolio alongside an oral formulation.

Clinical Advancements and Studies: The company is progressing with clinical trials for both the oral and topical formulations of Ketamir-2, with significant milestones expected this year, including studies on diabetic neuropathy and potential applications in treating PTSD.

MindMed Q4 Earnings Report: Mind Medicine reported a fourth quarter loss per share of (41c), exceeding analyst estimates, but highlighted significant progress in its clinical programs and sufficient cash reserves to fund operations until 2027.

Clinical Trials Updates: MIRA Pharmaceuticals announced the approval for a Phase 1 trial of Ketamir-2 for neuropathic pain, while atai Life Sciences completed enrollment for a Phase 2b trial of BPL-003 for treatment-resistant depression, with results expected in mid-2025.

MIRA Pharmaceuticals' Clinical Trial Approval: The Israeli Ministry of Health and the IRB have approved MIRA Pharmaceuticals' Phase 1 trial for Ketamir-2, a novel oral ketamine analog aimed at treating neuropathic pain, with human trials expected to start in early 2025.

Broader Potential and Market Growth: In addition to neuropathic pain, MIRA is exploring Ketamir-2 for PTSD and localized pain relief, with the neuropathic pain market projected to reach $5.2 billion in North America by 2030.

MIRA Pharmaceuticals IND Submission: MIRA Pharmaceuticals has submitted an Investigational New Drug application to the FDA for Ketamir-2, a novel oral ketamine analog aimed at treating neuropathic pain, with plans to initiate human trials in Q1 2025.

Market Potential and Future Plans: The North American neuropathic pain market is valued at $3.1 billion and expected to grow significantly; MIRA is also exploring additional indications for Ketamir-2 and advancing another drug, MIRA-55, targeting cognitive issues.

MIRA Pharmaceuticals Progress: MIRA Pharmaceuticals has completed the preclinical safety program for its oral ketamine analog, Ketamir-2, confirming a robust safety profile and paving the way for an Investigational New Drug application by the end of 2024.

Upcoming Clinical Trials: A Phase 1 trial is set to begin in Q1 2025 to assess Ketamir-2's safety and efficacy in healthy subjects, followed by a Phase 2a study focusing on neuropathic pain patients anticipated to start in Q4 2025.

MIRA Pharmaceuticals' Ketamir-2 Findings: MIRA Pharmaceuticals announced that their oral ketamine analog, Ketamir-2, is 60% more effective than gabapentin in alleviating chemotherapy-induced pain in preclinical studies, showing near-complete normalization of pain sensitivity in mice.

Future Development Plans: The company plans to submit an Investigational New Drug application by the end of 2024 and initiate Phase I clinical trials in early 2025, while also exploring multiple Phase 2 trials for neuropathic pain and evaluating Ketamir-2 for PTSD.

Real-time Intelligence for Traders: Benzinga Pro offers fast and accurate stock market intelligence, helping traders stay informed and make winning trades daily.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

MIRA Pharmaceuticals' Ketamir-2 Development: MIRA Pharmaceuticals announced promising preclinical data for its lead product, Ketamir-2, which demonstrated a 100% reversal of neuropathic pain in models. The drug is an oral ketamine analog that targets the NMDA receptor with fewer side effects than traditional treatments.

Future Plans and Market Response: The company plans to submit an Investigational New Drug application to the FDA by December 2024 and aims to begin human efficacy studies by 2025. Following the announcement, MIRA shares rose by 8.41% to $1.16.

MIRA Pharmaceuticals' Ketamir-2 Study Results: MIRA Pharmaceuticals Inc. reported that its oral ketamine analog, Ketamir-2, significantly reversed neuropathic pain in a preclinical study, achieving 100% normalization of pain thresholds at higher doses, unlike traditional oral ketamine which was ineffective.

Stock Performance and Future Plans: Following the positive study results, MIRA's stock rose by 39.4%, and the company is optimistic about further studies evaluating Ketamir-2 for cancer-induced depression and plans to advance towards clinical trials, potentially demonstrating human efficacy by 2025.

Health Care Stocks Performance: Health care stocks showed positive movement pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) increasing by 0.2% and the iShares Biotechnology ETF (IBB) rising by 0.6%.

Company Updates: BeiGene's shares rose over 3% following FDA fast-track designation for its leukemia treatment, while Guardant Health's shares fell more than 5% due to a planned $400 million share sale; MIRA Pharmaceuticals saw a 37% increase after promising pre-clinical study results for its ketamine analog.

MIRA Pharmaceuticals Stock Surge: MIRA Pharmaceuticals saw a significant 44.8% increase in pre-market trading after announcing successful results from a rat study on oral Ketamin-2 for neuropathic pain reversal.

Market Movers: Several stocks experienced notable gains and losses in pre-market trading, with MEDIROM Healthcare Technologies rising 135.5% and Talis Biomedical Corp declining 14.8% following Nasdaq's concerns about its listing status.

Earnings Reports Anticipated: PDD Holdings is expected to report earnings of $2.73 per share, while Daqo New Energy anticipates a loss of 56 cents per share; both companies will release their quarterly results before the market opens.

Stock Movements: MIRA Pharmaceuticals saw a significant increase of 47% in after-hours trading following positive study results, while HEICO Corporation and Trip.com Group experienced slight declines and gains respectively in after-hours trading.

Promising Results for Ketamir-2: MIRA Pharmaceuticals reported successful pre-clinical results for its oral ketamine analog, Ketamir-2, which significantly reversed neuropathic pain in a rat model, with effects lasting up to 22 days post-treatment.

Market Reaction and Future Potential: Following the announcement, MIRA's stock saw a notable increase in after-hours trading, reflecting investor optimism about Ketamir-2's potential to transform neuropathic pain treatment and its progression towards clinical development.

Mira Pharmaceuticals Q2 2024 Earnings: Mira Pharmaceuticals reported a second quarter earnings per share of -11 cents, falling short of the analyst estimate of -10 cents, and did not generate any revenue for the quarter.

InvestorPlace Earnings Coverage: InvestorPlace Earnings utilizes automated data from TradeSmith to provide timely coverage of quarterly earnings reports, highlighting key financial metrics without human intervention.

Leadership Changes at Telomir: Erez Aminov has been appointed as the new CEO and Chairman of Telomir Pharmaceuticals following the passing of former Chairman Christopher Chapman, Jr. Three directors have resigned from the board, while three new members have been appointed to support the transition.

Company Focus: Telomir Pharmaceuticals is a pre-clinical-stage company dedicated to developing Telomir-1, a drug aimed at promoting longevity by addressing age-related conditions in humans and dogs through the protection of telomeres.

Breakthrough in Neurological Treatments: MIRA Pharmaceuticals has announced promising preclinical data for its drug candidate Ketamir-2 and its metabolite Nor-Ketamir-2, which show nearly 100% oral bioavailability and improved safety profiles compared to traditional ketamine, potentially allowing for effective at-home treatments for neurological disorders.

Regulatory Progress and Future Plans: The company is advancing towards submitting an Investigational New Drug (IND) application by the end of the year, aiming to expedite clinical trials for indications such as cancer neuropathic pain and PTSD, while also developing a novel oral pharmaceutical marijuana analog, MIRA-55.

Kellanova Acquisition Interest: Kellanova shares surged 14.5% in pre-market trading amid reports that Mars is considering acquiring the company.

Stock Movements: Various stocks experienced significant pre-market trading changes, with MGO Global rising 38.4% and Aqua Metals plummeting 60%.

Most Searched Stocks: Tesla regained its position as the most searched stock on Benzinga Pro for July 2024, while NVIDIA and SPDR S&P 500 ETF Trust followed closely behind. Newcomers to the top 10 include Serve Robotics and Zapp Electric Vehicles.

Market Trends: CrowdStrike faced negative attention due to a significant update affecting Windows products, while GameStop fell out of the top 20 after previously ranking higher. The iShares Russell 2000 ETF is gaining interest as investors consider small-cap stocks amidst potential market shifts.